TCTR20160321001已完成2 期
Immunomodulation effects of early therapeutic normothermia in febrile severe septic patients
Faculty of Medicine, Chulalongkorn University0 个研究点目标入组 15 人开始时间: 2016年3月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 0 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. Diagnosis of severe sepsis by the definition of Surviving Sepsis Campaign Guideline 2012
- •2. Body temperature more than 38.3 degree-Celsius
- •3. Serum lactate > 4mmol/L or systolic blood pressure less than 90 mmHg after 1 litres of intravenous fluid or need vasopressor to maintain systolic blood pressure more than 90 mmHg
排除标准
- •1. expected to be deceased within 24 hours
- •2. Terminally ill patients that do not want to be resuscitated
- •3. Causative organism suspected to be from other organisms other than bacteria
- •4. Pregnant patients
- •5. Immunocompromised such as HIV, post-splecnectomy, neutropenia, on immunosupressive agent
- •6. Transferred from other hospitals
- •7. Diagnosis of severe sepsis more than 12 hours
- •8. Patients with acute brain injury
研究者
相似试验
已完成
4 期
Assessment of Immune Modulation after use of NANO SOMACTRI/2021/10/037180DrPRRaghavan26
已完成
2 期
To study the effect of Swarnaprashan in reducing the frequency of illness in children by improving the immunity and increasing the body strength.CTRI/2021/05/033713ational Institute of Ayurveda Jaipur Rajasthan30
进行中（未招募）
1 期
ICAR (IgIV in Covid-related ARds)Cov-2 SARS DiseaseMedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862EUCTR2020-001570-30-FRGHU PARIS PSYCHIATRIE ET NEUROSCIENCES126
已完成
4 期
Characterization of the immuno-modulatory effects of Tecfidera in multiple sclerosis patients: exploration of drug mechanism and methodological feasibility.Reduced lymphocyte count. Reduced white bloodcell count.10047954NL-OMON42490Centre for Human Drug Research16
已完成
不适用
Validation study of the immunomodulatory effects of ResistAid™ImmunomodulationHaematological DisordersISRCTN12127589onza (USA)75